Huons Global reported consolidated sales of 190.6 billion won ($142.9 million) and operating income of 31.9 billion won ($24 million) for the third quarter of this year, up 13.8 percent and 75 percent, respectively, from the same period last year. The group's performance was driven by increased international sales of its subsidiaries Huons, Humedix, and HuM&C.

Huons, the pharmaceutical company, posted sales of 138.2 billion won and operating profit of 15 billion won, up 12 percent and 638 percent, respectively, year-on-year. Sales in the prescription medicine division grew 26 percent year-on-year to 66.5 billion won, with sales of injectables exported to the U.S. up 97 percent year-on-year to 6.1 billion won.

The contract manufacturing organization (CMO) business also grew 14.7 percent on-year to 17.1 billion won in sales. Huons is conducting trial production ahead of the full-scale operation of the eye drops line at its second factory in Jecheon, North Chungcheong Province, increasing production capacity.

In response to the growing demand for dry eye treatment, Huons plans to reaffirm its position as a leading eye drops manufacturer. In addition, the company targets to increase its market share in the U.S. by expanding its injectable line at its second plant.

Humedix, the medical device and cosmetics firm, also continued its strong performance in the third quarter with sales of 39.7 billion won and operating profit of 11.4 billion won, up 24 percent and 45 percent year-on-year, respectively. Growth in the dermal fillers, CMO, and cosmetics businesses drove the performance, the company said. In particular, demand for dermal fillers surged in China and South America.

HuM&C,  the manufacturer of makeup sponges and puffs, also posted 12.6 billion won in sales and 1.5 billion won in operating profit in the third quarter, up 22 percent and 327 percent year-on-year, respectively.

The increase in international sales was attributed to continuous activities at overseas trade fairs and positive responses from local markets. HuM&C targets to increase its profit margin with the strong performance of its cosmetics division and the completion of its production base in Vietnam.

"Huons Group is focused on growth and profitability based on innovation," CEO Song Soo-young said. "Based on our export expansion strategy, which contributed to our strong performance in the third quarter, we will continue to strive to provide high-quality medicines to the world."